CN116829109A - 用于新颖视网膜辐照度分布修改以改善及恢复视力而不产生角膜玻璃化的装置及方法 - Google Patents
用于新颖视网膜辐照度分布修改以改善及恢复视力而不产生角膜玻璃化的装置及方法 Download PDFInfo
- Publication number
- CN116829109A CN116829109A CN202080108398.4A CN202080108398A CN116829109A CN 116829109 A CN116829109 A CN 116829109A CN 202080108398 A CN202080108398 A CN 202080108398A CN 116829109 A CN116829109 A CN 116829109A
- Authority
- CN
- China
- Prior art keywords
- retinal
- eye
- retina
- vision
- ambient light
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002207 retinal effect Effects 0.000 title claims abstract description 565
- 238000000034 method Methods 0.000 title claims abstract description 294
- 230000004438 eyesight Effects 0.000 title claims abstract description 184
- 230000004048 modification Effects 0.000 title claims description 89
- 238000012986 modification Methods 0.000 title claims description 89
- 238000004017 vitrification Methods 0.000 title claims description 9
- 238000009826 distribution Methods 0.000 title description 40
- 230000004287 retinal location Effects 0.000 claims abstract description 86
- 210000004087 cornea Anatomy 0.000 claims description 158
- 210000001525 retina Anatomy 0.000 claims description 150
- 210000004027 cell Anatomy 0.000 claims description 108
- 230000003287 optical effect Effects 0.000 claims description 83
- 230000006399 behavior Effects 0.000 claims description 34
- 238000005259 measurement Methods 0.000 claims description 19
- 230000002441 reversible effect Effects 0.000 claims description 17
- 230000006735 deficit Effects 0.000 claims description 14
- 230000005855 radiation Effects 0.000 claims description 11
- 210000000130 stem cell Anatomy 0.000 claims description 10
- 230000001973 epigenetic effect Effects 0.000 claims description 9
- 238000000059 patterning Methods 0.000 claims description 8
- 230000004377 improving vision Effects 0.000 claims description 6
- 230000000626 neurodegenerative effect Effects 0.000 claims description 5
- 239000003623 enhancer Substances 0.000 claims description 4
- 230000000007 visual effect Effects 0.000 abstract description 69
- 201000004569 Blindness Diseases 0.000 abstract description 28
- 230000001537 neural effect Effects 0.000 abstract description 25
- 230000008447 perception Effects 0.000 abstract description 17
- 230000010354 integration Effects 0.000 abstract description 8
- 230000000638 stimulation Effects 0.000 abstract description 7
- 208000029257 vision disease Diseases 0.000 abstract description 4
- 238000005070 sampling Methods 0.000 abstract description 2
- 210000001508 eye Anatomy 0.000 description 299
- 210000000695 crystalline len Anatomy 0.000 description 90
- 238000011282 treatment Methods 0.000 description 78
- 230000008569 process Effects 0.000 description 39
- 206010064930 age-related macular degeneration Diseases 0.000 description 36
- 108091008695 photoreceptors Proteins 0.000 description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 34
- 208000022873 Ocular disease Diseases 0.000 description 33
- 230000006872 improvement Effects 0.000 description 32
- 230000002829 reductive effect Effects 0.000 description 27
- 102000008186 Collagen Human genes 0.000 description 26
- 108010035532 Collagen Proteins 0.000 description 26
- 230000008859 change Effects 0.000 description 26
- 229920001436 collagen Polymers 0.000 description 26
- 208000002780 macular degeneration Diseases 0.000 description 26
- 230000004393 visual impairment Effects 0.000 description 25
- 230000006378 damage Effects 0.000 description 24
- 230000001603 reducing effect Effects 0.000 description 24
- 208000008069 Geographic Atrophy Diseases 0.000 description 22
- 208000017442 Retinal disease Diseases 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 208000003098 Ganglion Cysts Diseases 0.000 description 20
- 208000005400 Synovial Cyst Diseases 0.000 description 20
- 201000010099 disease Diseases 0.000 description 20
- 238000012545 processing Methods 0.000 description 20
- 230000035945 sensitivity Effects 0.000 description 20
- 230000004304 visual acuity Effects 0.000 description 20
- 230000004424 eye movement Effects 0.000 description 19
- 238000002560 therapeutic procedure Methods 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- 238000002679 ablation Methods 0.000 description 18
- 210000004556 brain Anatomy 0.000 description 18
- 230000002123 temporal effect Effects 0.000 description 18
- 208000010412 Glaucoma Diseases 0.000 description 17
- 230000001413 cellular effect Effects 0.000 description 17
- 206010012689 Diabetic retinopathy Diseases 0.000 description 16
- 239000004973 liquid crystal related substance Substances 0.000 description 15
- 230000009286 beneficial effect Effects 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 14
- 230000002093 peripheral effect Effects 0.000 description 14
- 238000010586 diagram Methods 0.000 description 13
- 210000003850 cellular structure Anatomy 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 230000008439 repair process Effects 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 210000003683 corneal stroma Anatomy 0.000 description 11
- 208000014674 injury Diseases 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 201000009487 Amblyopia Diseases 0.000 description 10
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 10
- 239000006185 dispersion Substances 0.000 description 10
- 210000003560 epithelium corneal Anatomy 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000002513 implantation Methods 0.000 description 10
- 238000011084 recovery Methods 0.000 description 10
- 230000008929 regeneration Effects 0.000 description 10
- 238000011069 regeneration method Methods 0.000 description 10
- 238000001356 surgical procedure Methods 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 238000002647 laser therapy Methods 0.000 description 9
- 238000013532 laser treatment Methods 0.000 description 9
- 230000033001 locomotion Effects 0.000 description 9
- 230000005043 peripheral vision Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000012549 training Methods 0.000 description 9
- 230000004400 visual pathway Effects 0.000 description 9
- 210000000239 visual pathway Anatomy 0.000 description 9
- 230000006978 adaptation Effects 0.000 description 8
- 230000003915 cell function Effects 0.000 description 8
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 8
- 230000001186 cumulative effect Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 210000000857 visual cortex Anatomy 0.000 description 8
- 206010025421 Macule Diseases 0.000 description 7
- 230000002411 adverse Effects 0.000 description 7
- 230000002939 deleterious effect Effects 0.000 description 7
- 230000004064 dysfunction Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 230000002459 sustained effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000004382 visual function Effects 0.000 description 7
- 201000007737 Retinal degeneration Diseases 0.000 description 6
- 238000003491 array Methods 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 210000001775 bruch membrane Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 230000000750 progressive effect Effects 0.000 description 6
- 239000000790 retinal pigment Substances 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 238000011269 treatment regimen Methods 0.000 description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 210000002287 horizontal cell Anatomy 0.000 description 5
- 210000004498 neuroglial cell Anatomy 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000002831 pharmacologic agent Substances 0.000 description 5
- 239000003504 photosensitizing agent Substances 0.000 description 5
- 208000014733 refractive error Diseases 0.000 description 5
- 210000003994 retinal ganglion cell Anatomy 0.000 description 5
- 239000002151 riboflavin Substances 0.000 description 5
- 235000019192 riboflavin Nutrition 0.000 description 5
- 229960002477 riboflavin Drugs 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010057430 Retinal injury Diseases 0.000 description 4
- 206010040030 Sensory loss Diseases 0.000 description 4
- 206010045178 Tunnel vision Diseases 0.000 description 4
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 210000000411 amacrine cell Anatomy 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 230000005779 cell damage Effects 0.000 description 4
- 208000037887 cell injury Diseases 0.000 description 4
- 230000004456 color vision Effects 0.000 description 4
- 230000001054 cortical effect Effects 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 208000030533 eye disease Diseases 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000009610 hypersensitivity Effects 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 230000004007 neuromodulation Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 210000001103 thalamus Anatomy 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 230000001228 trophic effect Effects 0.000 description 4
- 230000016776 visual perception Effects 0.000 description 4
- 208000001351 Epiretinal Membrane Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000001344 Macular Edema Diseases 0.000 description 3
- 206010025412 Macular dystrophy congenital Diseases 0.000 description 3
- 206010025415 Macular oedema Diseases 0.000 description 3
- 210000005156 Müller Glia Anatomy 0.000 description 3
- 208000029091 Refraction disease Diseases 0.000 description 3
- 208000002367 Retinal Perforations Diseases 0.000 description 3
- 206010038910 Retinitis Diseases 0.000 description 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 3
- 208000027073 Stargardt disease Diseases 0.000 description 3
- 230000004430 ametropia Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000009246 art therapy Methods 0.000 description 3
- 230000001851 biosynthetic effect Effects 0.000 description 3
- -1 but not limited to Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000004300 dark adaptation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000004410 intraocular pressure Effects 0.000 description 3
- 230000004301 light adaptation Effects 0.000 description 3
- 208000029233 macular holes Diseases 0.000 description 3
- 201000010230 macular retinal edema Diseases 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 210000000327 mueller cell Anatomy 0.000 description 3
- 208000001491 myopia Diseases 0.000 description 3
- 230000004379 myopia Effects 0.000 description 3
- 230000004297 night vision Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 230000000649 photocoagulation Effects 0.000 description 3
- 230000008832 photodamage Effects 0.000 description 3
- 210000004694 pigment cell Anatomy 0.000 description 3
- 230000010287 polarization Effects 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000001747 pupil Anatomy 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 208000004644 retinal vein occlusion Diseases 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000007493 shaping process Methods 0.000 description 3
- 230000002739 subcortical effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000134916 Amanita Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 229940124073 Complement inhibitor Drugs 0.000 description 2
- 206010012667 Diabetic glaucoma Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 description 2
- 108010072051 Glatiramer Acetate Proteins 0.000 description 2
- 229940122459 Glutamate antagonist Drugs 0.000 description 2
- 208000032984 Intraoperative Complications Diseases 0.000 description 2
- 206010063185 Macular scar Diseases 0.000 description 2
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- DAYLJWODMCOQEW-TURQNECASA-O NMN(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-O 0.000 description 2
- 208000001140 Night Blindness Diseases 0.000 description 2
- 102100036220 PC4 and SFRS1-interacting protein Human genes 0.000 description 2
- 102100031248 Patatin-like phospholipase domain-containing protein 2 Human genes 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 208000035965 Postoperative Complications Diseases 0.000 description 2
- 206010057765 Procedural complication Diseases 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 2
- 210000002159 anterior chamber Anatomy 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000004900 autophagic degradation Effects 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 210000004227 basal ganglia Anatomy 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000006727 cell loss Effects 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000004074 complement inhibitor Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 2
- 229960002224 eculizumab Drugs 0.000 description 2
- 239000011263 electroactive material Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000005262 ferroelectric liquid crystals (FLCs) Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 229960001347 fluocinolone acetonide Drugs 0.000 description 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 description 2
- 229960003776 glatiramer acetate Drugs 0.000 description 2
- 239000003825 glutamate receptor antagonist Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000001153 interneuron Anatomy 0.000 description 2
- 108010093345 lens epithelium-derived growth factor Proteins 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000006609 metabolic stress Effects 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 230000004065 mitochondrial dysfunction Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000020956 nicotinamide riboside Nutrition 0.000 description 2
- 239000011618 nicotinamide riboside Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 238000006303 photolysis reaction Methods 0.000 description 2
- 208000007578 phototoxic dermatitis Diseases 0.000 description 2
- 231100000018 phototoxicity Toxicity 0.000 description 2
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 210000000977 primary visual cortex Anatomy 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 210000001210 retinal vessel Anatomy 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000002645 vision therapy Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 1
- 239000005660 Abamectin Substances 0.000 description 1
- 229940122614 Adenosine receptor agonist Drugs 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000036693 Color-vision disease Diseases 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 108010028773 Complement C5 Proteins 0.000 description 1
- 206010052117 Corneal decompensation Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 229910052689 Holmium Inorganic materials 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 229920000106 Liquid crystal polymer Polymers 0.000 description 1
- 239000004977 Liquid-crystal polymers (LCPs) Substances 0.000 description 1
- 208000010415 Low Vision Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 239000004697 Polyetherimide Substances 0.000 description 1
- 208000034461 Progressive cone dystrophy Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- CIOAGBVUUVVLOB-NJFSPNSNSA-N Strontium-90 Chemical compound [90Sr] CIOAGBVUUVVLOB-NJFSPNSNSA-N 0.000 description 1
- 229910052775 Thulium Inorganic materials 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047555 Visual field defect Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000000333 X-ray scattering Methods 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- ISQINHMJILFLAQ-UHFFFAOYSA-N argon hydrofluoride Chemical compound F.[Ar] ISQINHMJILFLAQ-UHFFFAOYSA-N 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229950006867 avacincaptad pegol Drugs 0.000 description 1
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000004915 chaperone-mediated autophagy Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 201000008615 cone dystrophy Diseases 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 210000000399 corneal endothelial cell Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000023077 detection of light stimulus Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000003989 dielectric material Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000011325 dry age related macular degeneration Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000002091 elastography Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 102000005396 glutamine synthetase Human genes 0.000 description 1
- 108020002326 glutamine synthetase Proteins 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000004886 head movement Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 230000004298 light response Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 230000004303 low vision Effects 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 238000012014 optical coherence tomography Methods 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 201000003841 peripheral retinal degeneration Diseases 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000007539 photo-oxidation reaction Methods 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920001601 polyetherimide Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 230000004647 pro-inflammatory pathway Effects 0.000 description 1
- 230000006482 proangiogenic pathway Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000004478 pupil constriction Effects 0.000 description 1
- 230000010344 pupil dilation Effects 0.000 description 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 208000024981 pyrosis Diseases 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000964 retinal cone photoreceptor cell Anatomy 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000004283 retinal dysfunction Effects 0.000 description 1
- 230000004256 retinal image Effects 0.000 description 1
- 230000004286 retinal pathology Effects 0.000 description 1
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 238000011268 retreatment Methods 0.000 description 1
- 102000000568 rho-Associated Kinases Human genes 0.000 description 1
- 108010041788 rho-Associated Kinases Proteins 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000010897 surface acoustic wave method Methods 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- FRNOGLGSGLTDKL-UHFFFAOYSA-N thulium atom Chemical compound [Tm] FRNOGLGSGLTDKL-UHFFFAOYSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229950001212 volociximab Drugs 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
- A61F2/145—Corneal inlays, onlays, or lenses for refractive correction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
- A61F2/16—Intraocular lenses
- A61F2/1613—Intraocular lenses having special lens configurations, e.g. multipart lenses; having particular optical properties, e.g. pseudo-accommodative lenses, lenses having aberration corrections, diffractive lenses, lenses for variably absorbing electromagnetic radiation, lenses having variable focus
- A61F2/1648—Multipart lenses
- A61F2/1651—Multipart lenses comprising a telescope
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H5/00—Exercisers for the eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
- A61F2009/00863—Retina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00897—Scanning mechanisms or algorithms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0053—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in optical properties
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C2202/00—Generic optical aspects applicable to one or more of the subgroups of G02C7/00
- G02C2202/10—Optical elements and systems for visual disorders other than refractive errors, low vision
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/02—Lenses; Lens systems ; Methods of designing lenses
- G02C7/04—Contact lenses for the eyes
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Rehabilitation Therapy (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Prostheses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/119,617 US11974945B2 (en) | 2017-08-31 | 2020-12-11 | Devices and methods for novel retinal irradiance distribution modification to improve and restore vision without producing corneal vitrification |
| PCT/US2020/064620 WO2022125116A1 (fr) | 2020-12-11 | 2020-12-11 | Dispositifs et procédés destinés à une nouvelle modification de distribution d'éclairement énergétique rétinienne afin d'améliorer et de restaurer la vision sans produire de vitrification de la cornée |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116829109A true CN116829109A (zh) | 2023-09-29 |
Family
ID=81973868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080108398.4A Pending CN116829109A (zh) | 2020-12-11 | 2020-12-11 | 用于新颖视网膜辐照度分布修改以改善及恢复视力而不产生角膜玻璃化的装置及方法 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4259054A4 (fr) |
| JP (1) | JP2024504245A (fr) |
| CN (1) | CN116829109A (fr) |
| AU (1) | AU2020480841A1 (fr) |
| CA (1) | CA3200780A1 (fr) |
| WO (1) | WO2022125116A1 (fr) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1171188B1 (fr) * | 1999-03-24 | 2009-05-06 | Second Sight Medical Products, Inc. | Prothese retinienne de couleur pour restituer la vision des couleurs |
| US8486055B2 (en) * | 2007-06-26 | 2013-07-16 | Bausch & Lomb Incorporated | Method for modifying the refractive index of ocular tissues |
| US20190060056A1 (en) * | 2017-08-31 | 2019-02-28 | Olivia Serdarevic | Devices and Methods for Novel Retinal Irradiance Distribution Modification to Improve and Restore Vision |
| EP3664747A4 (fr) * | 2017-09-14 | 2021-04-28 | Board Of Trustees Of The University Of Illinois | Dispositifs, systèmes et méthodes de restauration de la vision |
| US10175490B1 (en) * | 2017-12-20 | 2019-01-08 | Aperture In Motion, LLC | Light control devices and methods for regional variation of visual information and sampling |
-
2020
- 2020-12-11 WO PCT/US2020/064620 patent/WO2022125116A1/fr active Application Filing
- 2020-12-11 CN CN202080108398.4A patent/CN116829109A/zh active Pending
- 2020-12-11 EP EP20965294.0A patent/EP4259054A4/fr active Pending
- 2020-12-11 CA CA3200780A patent/CA3200780A1/fr active Pending
- 2020-12-11 AU AU2020480841A patent/AU2020480841A1/en active Pending
- 2020-12-11 JP JP2023535559A patent/JP2024504245A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022125116A1 (fr) | 2022-06-16 |
| AU2020480841A9 (en) | 2024-05-09 |
| EP4259054A4 (fr) | 2024-09-04 |
| AU2020480841A1 (en) | 2023-07-27 |
| CA3200780A1 (fr) | 2022-06-16 |
| JP2024504245A (ja) | 2024-01-31 |
| EP4259054A1 (fr) | 2023-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11982815B2 (en) | Light control devices and methods for regional variation of visual information and sampling | |
| RU2664193C1 (ru) | Конструкция положительной линзы с подачей импульса для контроля миопии, увеличенной глубины резкости и коррекции пресбиопии | |
| US11766354B2 (en) | Devices and methods for novel retinal irradiance distribution modification to improve and restore vision without producing corneal vitrification | |
| US10386646B1 (en) | Light control devices and methods for regional variation of visual information and sampling | |
| JP6773557B2 (ja) | 角膜ガラス化を生成する方法及びデバイス、並びにそれらの利用の方法 | |
| US20020049450A1 (en) | Correction of presbyopia, other refractive errors and cataract retardation | |
| EP2886113A1 (fr) | Composition ophtalmique pour la correction de la presbytie | |
| US11974945B2 (en) | Devices and methods for novel retinal irradiance distribution modification to improve and restore vision without producing corneal vitrification | |
| WO2017039488A1 (fr) | Méthode d'opérations chirurgicales ophtalmologiques utilisant un autogreffon | |
| CN116829109A (zh) | 用于新颖视网膜辐照度分布修改以改善及恢复视力而不产生角膜玻璃化的装置及方法 | |
| US20210311324A1 (en) | Device and method for creating an aperture diaphragm in an intraocular lens | |
| Stein et al. | Surgical Correction of Presbyopia: A Focus on New Techniques | |
| CN105498097A (zh) | 一种角膜交联仪 | |
| RU2819741C1 (ru) | Способ хирургического лечения катаракты или факосклероза посредством фемтосекундного лазера (ФСЛ) с профилактикой интраоперационного миоза | |
| Ting et al. | Improvement in accommodation and dynamic range of focus after laser scleral microporation: A potential treatment for presbyopia. Transl Vis Sci Technol. 2022; 11 (12): 2 | |
| WO2022059757A1 (fr) | Dispositif et procédé d'inhibition d'amincissement choroïdien | |
| Isroilova et al. | AN INNOVATIVE THERAPEUTIC TOOL IN BIOPHYSICS IN THE FIELD OF MEDICINE (LASIK) | |
| JP2021500967A (ja) | 眼にアパーチャを生成するためのデバイス |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40101483 Country of ref document: HK |